187 related articles for article (PubMed ID: 21445359)
1. The Ras antagonist, farnesylthiosalicylic acid (FTS), decreases fibrosis and improves muscle strength in dy/dy mouse model of muscular dystrophy.
Nevo Y; Aga-Mizrachi S; Elmakayes E; Yanay N; Ettinger K; Elbaz M; Brunschwig Z; Dadush O; Elad-Sfadia G; Haklai R; Kloog Y; Chapman J; Reif S
PLoS One; 2011 Mar; 6(3):e18049. PubMed ID: 21445359
[TBL] [Abstract][Full Text] [Related]
2. Losartan, a therapeutic candidate in congenital muscular dystrophy: studies in the dy(2J) /dy(2J) mouse.
Elbaz M; Yanay N; Aga-Mizrachi S; Brunschwig Z; Kassis I; Ettinger K; Barak V; Nevo Y
Ann Neurol; 2012 May; 71(5):699-708. PubMed ID: 22522482
[TBL] [Abstract][Full Text] [Related]
3. The Ras antagonist, farnesylthiosalicylic acid (FTS), inhibits experimentally-induced liver cirrhosis in rats.
Reif S; Weis B; Aeed H; Gana-Weis M; Zaidel L; Avni Y; Romanelli RG; Pinzani M; Kloog Y; Bruck R
J Hepatol; 1999 Dec; 31(6):1053-61. PubMed ID: 10604579
[TBL] [Abstract][Full Text] [Related]
4. Omigapil treatment decreases fibrosis and improves respiratory rate in dy(2J) mouse model of congenital muscular dystrophy.
Yu Q; Sali A; Van der Meulen J; Creeden BK; Gordish-Dressman H; Rutkowski A; Rayavarapu S; Uaesoontrachoon K; Huynh T; Nagaraju K; Spurney CF
PLoS One; 2013; 8(6):e65468. PubMed ID: 23762378
[TBL] [Abstract][Full Text] [Related]
5. Improved muscle strength and mobility in the dy(2J)/dy(2J) mouse with merosin deficient congenital muscular dystrophy treated with Glatiramer acetate.
Dadush O; Aga-Mizrachi S; Ettinger K; Tabakman R; Elbaz M; Fellig Y; Yanay N; Nevo Y
Neuromuscul Disord; 2010 Apr; 20(4):267-72. PubMed ID: 20304648
[TBL] [Abstract][Full Text] [Related]
6. Prevention of induced colitis in mice by the ras antagonist farnesylthiosalicylic acid.
Oron T; Elad-Sfadia G; Haklai R; Aizman E; Brazowski E; Kloog Y; Reif S
Dig Dis Sci; 2012 Feb; 57(2):320-6. PubMed ID: 21901261
[TBL] [Abstract][Full Text] [Related]
7. Functional inhibition of Ras by S-trans,trans-farnesyl thiosalicylic acid attenuates atherosclerosis in apolipoprotein E knockout mice.
George J; Afek A; Keren P; Herz I; Goldberg I; Haklai R; Kloog Y; Keren G
Circulation; 2002 May; 105(20):2416-22. PubMed ID: 12021230
[TBL] [Abstract][Full Text] [Related]
8. Treatment of MRL/lpr mice, a genetic autoimmune model, with the Ras inhibitor, farnesylthiosalicylate (FTS).
Katzav A; Kloog Y; Korczyn AD; Niv H; Karussis DM; Wang N; Rabinowitz R; Blank M; Shoenfeld Y; Chapman J
Clin Exp Immunol; 2001 Dec; 126(3):570-7. PubMed ID: 11737078
[TBL] [Abstract][Full Text] [Related]
9. Ras antagonist farnesylthiosalicylic acid (FTS) reduces glomerular cellular proliferation and macrophage number in rat thy-1 nephritis.
Clarke HC; Kocher HM; Khwaja A; Kloog Y; Cook HT; Hendry BM
J Am Soc Nephrol; 2003 Apr; 14(4):848-54. PubMed ID: 12660318
[TBL] [Abstract][Full Text] [Related]
10. RAS Promotes Proliferation and Resistances to Apoptosis in Meningioma.
Jiang C; Song T; Li J; Ao F; Gong X; Lu Y; Zhang C; Chen L; Liu Y; He H; Huang O
Mol Neurobiol; 2017 Jan; 54(1):779-787. PubMed ID: 27021020
[TBL] [Abstract][Full Text] [Related]
11. The effect of Ras inhibition on the proliferation, apoptosis and matrix metalloproteases activity in rat hepatic stellate cells.
Zvibel I; Bar-Zohar D; Kloog Y; Oren R; Reif S
Dig Dis Sci; 2008 Apr; 53(4):1048-53. PubMed ID: 17934818
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotective Effect of S-trans, Trans-farnesylthiosalicylic Acid via Inhibition of RAS/ERK Pathway for the Treatment of Alzheimer's Disease.
Wang X; Wang Y; Zhu Y; Yan L; Zhao L
Drug Des Devel Ther; 2019; 13():4053-4063. PubMed ID: 31819374
[TBL] [Abstract][Full Text] [Related]
13. The Ras inhibitor S-trans,trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance.
Gana-Weisz M; Halaschek-Wiener J; Jansen B; Elad G; Haklai R; Kloog Y
Clin Cancer Res; 2002 Feb; 8(2):555-65. PubMed ID: 11839677
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotective effects of the Ras inhibitor S-trans-trans-farnesylthiosalicylic acid, measured by diffusion-weighted imaging after traumatic brain injury in rats.
Marciano D; Shohami E; Kloog Y; Alexandrovitch A; Brandeis R; Goelman G
J Neurotrauma; 2007 Aug; 24(8):1378-86. PubMed ID: 17711399
[TBL] [Abstract][Full Text] [Related]
15. Improvement of motor conduction velocity in hereditary neuropathy of LAMA2-CMD dy
Rabie M; Yanay N; Fellig Y; Konikov-Rozenman J; Nevo Y
Clin Neurophysiol; 2019 Oct; 130(10):1988-1994. PubMed ID: 31476705
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D and S-farnesylthiosalicylic acid have a synergistic effect on hepatic stellate cells proliferation.
Neeman R; Abramovitch S; Sharvit E; Elad-Sfadia G; Haklai R; Kloog Y; Reif S
Dig Dis Sci; 2014 Oct; 59(10):2462-9. PubMed ID: 24942325
[TBL] [Abstract][Full Text] [Related]
17. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
Barkan B; Starinsky S; Friedman E; Stein R; Kloog Y
Clin Cancer Res; 2006 Sep; 12(18):5533-42. PubMed ID: 17000690
[TBL] [Abstract][Full Text] [Related]
18. Ras inhibition in hepatocarcinoma by S-trans-trans-farnesylthiosalicyclic acid: association of its tumor preventive effect with cell proliferation, cell cycle events, and angiogenesis.
Stärkel P; Charette N; Borbath I; Schneider-Merck T; De Saeger C; Abarca J; Leclercq I; Horsmans Y
Mol Carcinog; 2012 Oct; 51(10):816-25. PubMed ID: 21882255
[TBL] [Abstract][Full Text] [Related]
19. Ras chaperones: new targets for cancer and immunotherapy.
Kloog Y; Elad-Sfadia G; Haklai R; Mor A
Enzymes; 2013; 33 Pt A():267-89. PubMed ID: 25033809
[TBL] [Abstract][Full Text] [Related]
20. Ras inhibitor S-trans, trans-farnesylthiosalicylic acid enhances spatial memory and hippocampal long-term potentiation via up-regulation of NMDA receptor.
Wang Y; Chen T; Yuan Z; Zhang Y; Zhang B; Zhao L; Chen L
Neuropharmacology; 2018 Sep; 139():257-267. PubMed ID: 29578035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
